AI Article Synopsis
- An amendment to the original paper has been published.
- The amendment can be accessed through a link provided at the top of the paper.
- Readers are encouraged to check the link for updated information.
Article Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608082 | PMC |
| http://dx.doi.org/10.1038/s41423-020-00537-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Can Artificial Intelligence Create an Accurate Colonoscopy Bowel Preparation Prompt?
Gastro Hep Adv
October 2024
Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, Mount Sinai South Nassau, One Healthy Way, Oceanside, New York.
Background And Aims: Colorectal cancer is the third most common cancer in the United States, with colonoscopy being the preferred screening method. Up to 25% of colonoscopies are associated with poor preparation which leads to prolonged procedure time, repeat colonoscopies, and decreased adenoma detection. Artificial intelligence (AI) is being increasingly used in medicine, assessing medical school exam questions, and writing medical reports.
View Article and Find Full Text PDFA Bayesian Joint Model of Multiple Nonlinear Longitudinal and Competing Risks Outcomes for Dynamic Prediction in Multiple Myeloma: Joint Estimation and Corrected Two-Stage Approaches.
Stat Med
February 2025
Hoffmann-La Roche Ltd, Basel, Switzerland.
Predicting cancer-associated clinical events is challenging in oncology. In Multiple Myeloma (MM), a cancer of plasma cells, disease progression is determined by changes in biomarkers, such as serum concentration of the paraprotein secreted by plasma cells (M-protein). Therefore, the time-dependent behavior of M-protein and the transition across lines of therapy (LoT), which may be a consequence of disease progression, should be accounted for in statistical models to predict relevant clinical outcomes.
View Article and Find Full Text PDFCirculating Tumor DNA as a Marker of Recurrence Risk in Stage III Colorectal Cancer: The α-CORRECT Study.
J Surg Oncol
January 2025
Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, and Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Background And Objectives: Identification of colorectal cancer (CRC) patients at high risk of recurrence could be of substantial clinical use. We evaluated the association of ctDNA status, using a tumor-informed assay, with recurrence-free survival (RFS).
Methods: Stage III CRC patients were enrolled between 2016 and 2020.
Correction: LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer.
Mol Cancer
January 2025
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Author Correction: Global loss of promoter-enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis.
Nat Cancer
January 2025
Department of Genetics, Stanford School of Medicine, Stanford, CA, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!